Anxiety Disorders
Neurology·MeSH: Anxiety Disorders
Prevalence
6090.6 / 100K
Incidence
716.2 / 100K/yr
6 drugs in development·6 companies·6 clinical trials
Drug Pipeline by Phase
Approved(2)
Phase 2(1)
| Drug | Company |
|---|---|
| Fluoxetine | Valneva SE (VALN) |
Phase 1(1)
| Drug | Company |
|---|---|
| ART26.12 | ARTELO BIOSCIENCES, INC. (ARTL) |
Preclinical(2)
Compare drugs
Frequently asked questions
How many drugs are in development for Anxiety Disorders?
BioSniper tracks 6 drugs in development for Anxiety Disorders across 6 companies.
How many clinical trials target Anxiety Disorders?
There are 6 clinical trials targeting Anxiety Disorders tracked by BioSniper.
What is the prevalence of Anxiety Disorders?
The estimated prevalence of Anxiety Disorders is approximately 6090.6 per 100,000 population.
Deep-dive into Anxiety Disorders
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis